Genomic Characterization of Breast Cancer Metastases Reveals Differences in Rates of PIK3CA Mutation Across Metastatic Sites and Worse Survival in Patients With Concurrent CDH1 Mutation Treated With PI3K Inhibitor
Publication
, Conference
Louie, AD; Bansal, R; Wu, S; Capelletti, M; Korn, WM; Kaklamani, V; Tan, A; Chalasani, P; El-Deiry, WS; Dizon, D; Graff, SL
Published in: ANNALS OF SURGICAL ONCOLOGY
2023
Duke Scholars
Published In
ANNALS OF SURGICAL ONCOLOGY
EISSN
1534-4681
ISSN
1068-9265
Publication Date
2023
Volume
30
Issue
SUPPL 1
Start / End Page
S62 / S62
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Louie, A. D., Bansal, R., Wu, S., Capelletti, M., Korn, W. M., Kaklamani, V., … Graff, S. L. (2023). Genomic Characterization of Breast Cancer Metastases Reveals Differences in Rates of PIK3CA Mutation Across Metastatic Sites and Worse Survival in Patients With Concurrent CDH1 Mutation Treated With PI3K Inhibitor. In ANNALS OF SURGICAL ONCOLOGY (Vol. 30, pp. S62–S62).
Louie, Anna D., Rani Bansal, Sharon Wu, Marzia Capelletti, W Michael Korn, Virginia Kaklamani, Antoinette Tan, et al. “Genomic Characterization of Breast Cancer Metastases Reveals Differences in Rates of PIK3CA Mutation Across Metastatic Sites and Worse Survival in Patients With Concurrent CDH1 Mutation Treated With PI3K Inhibitor.” In ANNALS OF SURGICAL ONCOLOGY, 30:S62–S62, 2023.
Louie AD, Bansal R, Wu S, Capelletti M, Korn WM, Kaklamani V, et al. Genomic Characterization of Breast Cancer Metastases Reveals Differences in Rates of PIK3CA Mutation Across Metastatic Sites and Worse Survival in Patients With Concurrent CDH1 Mutation Treated With PI3K Inhibitor. In: ANNALS OF SURGICAL ONCOLOGY. 2023. p. S62–S62.
Louie, Anna D., et al. “Genomic Characterization of Breast Cancer Metastases Reveals Differences in Rates of PIK3CA Mutation Across Metastatic Sites and Worse Survival in Patients With Concurrent CDH1 Mutation Treated With PI3K Inhibitor.” ANNALS OF SURGICAL ONCOLOGY, vol. 30, no. SUPPL 1, 2023, pp. S62–S62.
Louie AD, Bansal R, Wu S, Capelletti M, Korn WM, Kaklamani V, Tan A, Chalasani P, El-Deiry WS, Dizon D, Graff SL. Genomic Characterization of Breast Cancer Metastases Reveals Differences in Rates of PIK3CA Mutation Across Metastatic Sites and Worse Survival in Patients With Concurrent CDH1 Mutation Treated With PI3K Inhibitor. ANNALS OF SURGICAL ONCOLOGY. 2023. p. S62–S62.
Published In
ANNALS OF SURGICAL ONCOLOGY
EISSN
1534-4681
ISSN
1068-9265
Publication Date
2023
Volume
30
Issue
SUPPL 1
Start / End Page
S62 / S62
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis